Pharmacokinetics and Tolerability of Vortioxetine (Lu AA21004) in Child and Adolescent Patients With Depressive or Anxiety Disorder

This is an interventional treatment trial for Depressive Disorder focused on measuring Children, Adolescents, Pharmacokinetic, Pharmacodynamic Read More

Inclusion Criteria:

• Patients with a DSM-IV-TR diagnosis of Depressive or Anxiety Disorder.
• The patient and parent(s)/legal representative(s) are able to comprehend and satisfactorily comply with the protocol requirements.
• Treatment with antidepressant therapy is warranted, as judged by the investigator.

Exclusion Criteria:

• The patient is pregnant or breast-feeding.
• The patient presents or has a history of an Axis I (DSM-IV-TR) diagnosis of Bipolar Disorder, Post Traumatic Stress Disorder (PTSD), Autism, Pervasive Developmental Disorder (PDD), Obsessive Compulsive Disorder (OCD) or Schizophrenia or Schizoaffective Disorder.
• The patient has not maintained a stable dose of a methylphenidate or amphetamine for their treatment of attention-deficit/hyperactivity disorder (ADHD) for a minimum of 4 weeks prior to the study treatment.
• The patient has a known mental retardation, or clinical evidence or known social or school history indicative of mental retardation.
• The patient is at significant risk of committing suicide based on history (for example previous suicide attempt) or according to the investigator's experience, or based on active suicidal ideation, intent or plan, item 4 or 5 of the Columbia-Suicide Severity Rating Scale (C-SSRS).
• The subject has any concurrent illness that may affect the particular target or absorption, distribution, and elimination of the investigational medicinal product (IMP).
• The patient meets DSM-IV-TR criteria for any psychoactive substance or alcohol use disorder.

Other inclusion and exclusion criteria may apply.